Q-omics provides the consensus-scored TRIM33 profile across patient tissues and cancer cell-line models. TRIM33 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRIM33 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, TRIM33 protein abundance shows 21,424 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LIHC, and GBM as cancer lineages where TRIM33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM33 survival associations across molecular data types. TRIM33 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM33 RNA expression–survival associations across cancer types. High TRIM33 expression shows unfavorable associations in LIHC and LGG, but favorable associations in KIRC, HNSC, READ and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRIM33 RNA expression.
This table summarizes TRIM33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRIM33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM33 shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in LIHC, BLCA and CHOL. The LIHC box plot shows higher TRIM33 RNA expression in tumor versus normal tissue (log2 FC = +0.958, t-test p < 0.001).
This table shows molecular features associated with TRIM33 in patient tissues and cancer cell lines. In patient samples, TRIM33 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
